Innate Pharma S.A.
NASDAQ: IPHA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan E. Dickinson
- Employees
- 181
- Headquarters
- Marseille, France
- IPO year
- 2019
- Market cap
- $178.4M
- Website
- https://www.innate-pharma.com
Loading IPHA…
Loading profile data…Frequently asked questions about IPHA
What does Innate Pharma S.A. (IPHA) do?
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and v...
Where does IPHA trade?
Innate Pharma S.A. (IPHA) trades on the NASDAQ Global Select.
What sector is IPHA in?
Innate Pharma S.A. (IPHA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Innate Pharma S.A.?
Jonathan E. Dickinson is the chief executive officer of Innate Pharma S.A. (IPHA).
Where is Innate Pharma S.A. headquartered?
Innate Pharma S.A. is headquartered in France.
Does IPHA pay a dividend?
Innate Pharma S.A. (IPHA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IPHA go public?
Innate Pharma S.A. (IPHA) completed its initial public offering in 2019.
Is IPHA an ADR?
Yes — IPHA is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Innate Pharma S.A. reporting and dividends follow the underlying issuer.